Psychedelic-assisted therapies (Psilocybin and MDMA) for treatment-resistant psychiatric disorders
International Health Sciences Review · 10.11.2026 · 2 (6)
DOI: 10.70164/ihsr.v2i6.268 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Health Sciences Review, online erschienen am 10.11.2026. Verfasst von Maria Luiza Góes Gurgel und 14 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To describe the pharmacological mechanisms, clinical efficacy, and safety of psilocybin- and MDMA-assisted therapies for depression and post-traumatic stress disorder (PTSD), while critically examining the methodological limitations of current evidence.
Methods
This narrative, non-systematic literature review was conducted between September and November 2026. PubMed/MEDLINE was searched for publications from January 2016 to November 2026. Randomized clinical trials, systematic reviews, meta-analyses, and studies addressing mechanisms of action and safety were considered. Twelve references were selected and qualitatively synthesized.
Results
Psilocybin demonstrated significant reductions in depressive symptoms, with a moderate pooled effect size (Hedges' g = 0.66). Evidence specifically concerning treatment-resistant depression remains limited. MDMA-assisted psychotherapy showed significant reductions in PTSD severity in two phase 3 trials, with favorable response and remission rates. Both interventions presented acceptable tolerability under controlled clinical conditions, although transient adverse effects were frequent. Serious adverse events were reported particularly among individuals with pre-existing neuropsychiatric conditions. Major limitations included difficulties with blinding, expectancy bias, uncertain long-term efficacy, and limited population diversity.
Conclusion
Psychedelic-assisted therapies represent promising investigational approaches in psychiatry. However, methodological limitations and safety uncertainties warrant clinical caution and further rigorous research before broader therapeutic implementation.
Zitieren
APA
Gurgel, M. L. G., Ferreira, A. L. C., Mello, L. D. C., Caldato, A. C., Canto, S. Z. D., Camilotti, P. B., Silva, M. R. F., Gomes, R. A., Wiltemburg, B. B., Perini, G. S., Bertipaglia, M. R., Matos, R. B. D., Orsi, E. S., Nacle, F. O., & Ribeiro, G. F. D. (2026). Psychedelic-assisted therapies (Psilocybin and MDMA) for treatment-resistant psychiatric disorders. International Health Sciences Review, 2(6). https://doi.org/10.70164/ihsr.v2i6.268
Vancouver
Gurgel MLG, Ferreira ALC, Mello LDC, Caldato AC, Canto SZD, Camilotti PB, et al. Psychedelic-assisted therapies (Psilocybin and MDMA) for treatment-resistant psychiatric disorders. International Health Sciences Review. 2026;2(6). doi:10.70164/ihsr.v2i6.268
BibTeX
@article{Gurgel2026,
author = {Gurgel, Maria Luiza Góes and Ferreira, Ana Luísa Carrijo and Mello, Luisa da Costa and Caldato, Amanda Comandolli and Canto, Sofia Zaher do and Camilotti, Pietra Brossi and Silva, Manuela Ruela Folino and Gomes, Raissa Assalin and Wiltemburg, Beatriz Bomfim and Perini, Giulia Spadone and Bertipaglia, Manoela Rosa and Matos, Rafaella Barcelos de and Orsi, Enzo Seletti and Nacle, Fernanda Oliveira and Ribeiro, Gabriela Fernandes Daniel},
title = {Psychedelic-assisted therapies (Psilocybin and MDMA) for treatment-resistant psychiatric disorders},
journal = {International Health Sciences Review},
year = {2026},
volume = {2},
number = {6},
doi = {10.70164/ihsr.v2i6.268}
}
EUVIMED